BioGenes GmbH, a global leader in host cell protein (HCP) assay development, announced that it has signed long-term agreements with distributors in India, USA and Canada, Japan and Middle/South America to offer its enhanced generic HCP assay CHO|360-HCP ELISA within their respective territories. Europe and the rest of the world will be served by BioGenes directly.
CHO|360-HCP ELISA greatly improves the detection of host cell proteins in CHO cells by employing differently prepared host cell protein antigens and antibodies from two species. CHO|360-HCP ELISA allows users for the first time to easily choose the antibodies that work best for a specific process.
Dagmar Schwertner, director of marketing at BioGenes, stated: “We are excited to partner with these premier distributors who will introduce CHO|360-HCP ELISA to their esteemed customer base. The distribution agreements will help leverage BioGenes’ sales and marketing capabilities to establish CHO|360-HCP ELISA as the preferred generic assay for HCP detection in CHO cells. BioGenes will be working closely with its distributors to ensure a high standard of service.”
BioGenes GmbH is a specialiser in highly sophisticated and customized antibody and immunoassay development and is an experienced and reliable partner for process development improvements in all areas of quality control, diagnostics and drug discovery. BioGenes is certified to meet the international requirements and regularities of quality assurance and animal welfare. The company maintains long-term relationships with research institutes, universities and biotechnology and pharmaceutical companies, including eight of the ten largest pharmaceutical companies in the world. The company has been evaluated by a leading global accounting and auditing firm to be one of the leading companies in host cell protein assay development.